Cadrenal Therapeutics, Inc. CVKD 深 沪
已收盘 10-30 16:00:00 美东时间
0.985
+0.042
+4.41%
华盛通- 最 高1.00
- 今 开0.94
- 成交量 8.07万股
- 最 低 0.94
- 昨 收 0.9434
- 总市值 351.41万
- 52周最高 13.0099
- 市盈率 静 --
- 换手率 2.26%
- 52周最低 0.8163
- 委 比 -70.37%
- 总股本 356.76万
- 历史最高 101.25
- 量 比 1.74
- 振 幅 6.36%
- 历史最低 0.8163
- 每 手 1
- 风险率 3.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of 27 cents per share, which beat the analyst consensus estimate of 20 cents per share. The company repor...
09-01 16:35
Cadrenal Therapeutics Consolidates Multi-Indication Strategy For Cardiac Acute Critical Care Franchise, With Focus On CAD-1005 For Both HIT And CSA-AKI
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal injury Dual-Indication Development and Commercialization Strategy Expands the Clinical...
08-03 20:31
Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin Recently presented Phase 2 CAD...
07-21 20:24
Cadrenal Therapeutics’ Late-Breaking Clinical Data From Phase 2 Study Of 12-LOX Inhibitor CAD-1005 Featured In Oral Presentation At ISTH 2026 Congress
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. Oral presentation by Principal Investigator Dr. Steven E. McKenzie highlighted CAD-...
07-13 21:01
Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH
Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, ...
06-24 20:04
Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000 U.S. patients annually, with n...
06-15 20:34
Cadrenal Therapeutics Announces Participation In BIO 2026; To Host Partnering Meetings To Discuss Development And Commercialization Opportunities For Differentiated Pipeline, Headlined By CAD-1005 And Tecarfarin
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential12-LOX could play a central
06-03 21:05
Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.62) by 35.8 percent. This is a 50.24 percent increase over losses of $(2.09) per share
05-07 21:00
Cadrenal Therapeutics Receives FDA Guidance For Phase 3 Trial Of CAD-1005 Heparin-Induced Thrombocytopenia Treatment
Cadrenal has completed its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005.The meeting with the FDA provided
04-30 20:37
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
